Premium
Invasive fungal infections in AML / MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis?
Author(s) -
Pomares Helena,
Arnan Montserrat,
SánchezOrtega Isabel,
Sureda Anna,
Duarte Rafael F.
Publication year - 2016
Publication title -
mycoses
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.13
H-Index - 69
eISSN - 1439-0507
pISSN - 0933-7407
DOI - 10.1111/myc.12500
Subject(s) - azacitidine , neutropenia , medicine , myelodysplastic syndromes , incidence (geometry) , aspergillosis , febrile neutropenia , myeloid leukemia , myeloid , immunology , chemotherapy , biology , bone marrow , biochemistry , gene expression , physics , gene , optics , dna methylation
Summary The aim of this study is to analyse the risk of invasive fungal infection ( IFI ) and the need for antifungal prophylaxis in patients with acute myeloid leukaemia and myelodysplastic syndromes ( AML / MDS ) treated with azacitidine. We retrospectively analysed the incidence of IFI according to EORTC ‐ MSG criteria in 121 consecutive AML / MDS patients receiving 948 azacitidine courses (median 5, range 1–43) between June 2007 and June 2015. Four cases of IFI (two possible, one probable aspergillosis and one proven candidemia) occurred in this series. The incidence rate of proven/probable IFI was 0.21% per treatment cycle and 1.6% per patient treated for the whole series, and 0.73% per treatment cycle and 4.1% per patient treated in those with severe neutropenia. Two patients died from IFI , leading to an IFI ‐attributable mortality rate of 1.65% per patient and 0.21% per treatment cycle. The numbers needed to treat with prophylaxis to prevent one case of IFI are 238 azacitidine cycles or 30 patients throughout their whole treatment course, and 137 azacitidine cycles or 24 patients among those with severe neutropenia. AML / MDS patients treated with azacitidine, including those with severe prolonged neutropenia, have a very low risk of IFI which does not justify the use of antifungal prophylaxis.